BR112022009559A2 - Estímulos que hiperativam células dendríticas residentes para imunoterapia do câncer - Google Patents

Estímulos que hiperativam células dendríticas residentes para imunoterapia do câncer

Info

Publication number
BR112022009559A2
BR112022009559A2 BR112022009559A BR112022009559A BR112022009559A2 BR 112022009559 A2 BR112022009559 A2 BR 112022009559A2 BR 112022009559 A BR112022009559 A BR 112022009559A BR 112022009559 A BR112022009559 A BR 112022009559A BR 112022009559 A2 BR112022009559 A2 BR 112022009559A2
Authority
BR
Brazil
Prior art keywords
hyperactivate
stimulus
cancer immunotherapy
dendritic cells
individual
Prior art date
Application number
BR112022009559A
Other languages
English (en)
Inventor
C Kagan Jonathan
Zhivaki Dania
Original Assignee
Childrens Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Medical Center filed Critical Childrens Medical Center
Publication of BR112022009559A2 publication Critical patent/BR112022009559A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

ESTÍMULOS QUE HIPERATIVAM CÉLULAS DENDRÍTICAS RESIDENTES PARA IMUNOTERAPIA DO CÂNCER. A presente invenção refere-se à imunoterapia do câncer, por exemplo, estimulação da terapia antitumoral mediada por células T. Consequentemente, são descritos aqui métodos de induzir ou potencializar uma resposta imune adaptativa a um câncer em um indivíduo e métodos de tratar câncer em um indivíduo. Em algumas modalidades, os métodos de células dendríticas hiperativas (DCs), que induzem respostas T auxiliares tipo I (THI) e de linfócito T citotóxico na ausência de imunidade TH2.
BR112022009559A 2019-11-18 2020-11-18 Estímulos que hiperativam células dendríticas residentes para imunoterapia do câncer BR112022009559A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962937073P 2019-11-18 2019-11-18
PCT/US2020/061133 WO2021102058A1 (en) 2019-11-18 2020-11-18 Stimuli that hyperactivate resident dendritic cells for cancer immunotherapy

Publications (1)

Publication Number Publication Date
BR112022009559A2 true BR112022009559A2 (pt) 2022-08-02

Family

ID=75981039

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009559A BR112022009559A2 (pt) 2019-11-18 2020-11-18 Estímulos que hiperativam células dendríticas residentes para imunoterapia do câncer

Country Status (10)

Country Link
US (1) US20230076515A1 (pt)
EP (1) EP4061409A4 (pt)
JP (1) JP2023502400A (pt)
KR (1) KR20220114556A (pt)
CN (1) CN114980919A (pt)
AU (1) AU2020386008A1 (pt)
BR (1) BR112022009559A2 (pt)
CA (1) CA3162096A1 (pt)
IL (1) IL293030A (pt)
WO (1) WO2021102058A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016206965B2 (en) * 2015-01-12 2021-03-04 Children's Medical Center Corporation Pro-inflammatory and adjuvant functions of toll-like receptor 4 antagonists
CN108697778B (zh) * 2016-02-16 2023-10-03 哈佛学院院长等 病原体疫苗及其生产和使用方法
CA3028654A1 (en) * 2016-06-27 2018-01-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Therapeutic antitumor combination of a tlr4 ligand with other treatments
WO2018067302A2 (en) * 2016-09-19 2018-04-12 North Western University Therapeutic effects of cellular delivery of small molecules and macromolecules with liposomal spherical nucleic acids
JP7355394B2 (ja) * 2018-05-03 2023-10-03 エル．イー．エー．エフ． ホールディングス グループ エルエルシー カロテノイド組成物およびその使用

Also Published As

Publication number Publication date
US20230076515A1 (en) 2023-03-09
JP2023502400A (ja) 2023-01-24
KR20220114556A (ko) 2022-08-17
AU2020386008A1 (en) 2022-06-02
EP4061409A1 (en) 2022-09-28
EP4061409A4 (en) 2023-12-27
IL293030A (en) 2022-07-01
WO2021102058A1 (en) 2021-05-27
CA3162096A1 (en) 2021-05-27
CN114980919A (zh) 2022-08-30

Similar Documents

Publication Publication Date Title
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
NZ741028A (en) Novel lactobacillus and composition for preventing, improving, or treating degenerative brain diseases or cognitive function disorders
CO2018005306A2 (es) Variantes del factor viii reducido con cpg, composiciones y métodos y usos para el tratamiento de trastornos de la hemostasia
BR112017019140A2 (pt) métodos de tratamento de câncer usando células t ativadas
BR112013014265B8 (pt) Molécula de ácido nucleico isolada, receptor antígeno quimérico isolado, e, vetor
BR112017011920A2 (pt) ?receptores de antígeno quimérico que direcionam receptor acoplado à proteína g e usos dos mesmos?
MX2020009359A (es) Sistemas de celulas terapeuticas y metodos para el tratamiento de cancer y enfermedades infecciosas.
BR112018001858A2 (pt) monócitos/macrófagos modificados que expressam receptores de antígeno quimérico e usos dos mesmos
BR112016029041A2 (pt) terapia de combinação com inibidores de glutaminase
MX2020001996A (es) Moleculas anti-cd137 y uso de estas.
BR112018007538A2 (pt) células exterminadoras naturais e células ilc3 e usos das mesmas
BR112017008696A2 (pt) métodos e composições para células exterminadoras naturais
BR112016023523A2 (pt) produtos de células t modificados em gene de composição definida
MX2019011148A (es) Metodos de tratamiento.
BR112016024352A2 (pt) ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria?
BR112017009475A2 (pt) métodos de seleção de uma linhagem de células t e de um doador das mesmas para terapia celular adotiva
BR112016016525A2 (pt) Método para indução de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+ em um indivíduo, método para melhorar uma condição em um indivíduo, e método para a produção de células treg (ctla-4+, cd4+, cd25+) foxp3+ e/ou células treg lap+
WO2018088875A3 (ko) 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물
AR104598A1 (es) Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
BR112016023688A2 (pt) célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada
PH12020550906A1 (en) Immunostimulatory oligonucleotides
BR112018010155A8 (pt) segmentação do receptor formil-peptídeo 2/receptor lipoxina a4 (fpr2/alx) para tratamento de doença cardíaca
MX2020009736A (es) Composiciones que comprenden cepas bacterianas.
BR112022009559A2 (pt) Estímulos que hiperativam células dendríticas residentes para imunoterapia do câncer